Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib

Abstract Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti‐MM activity in preclinical studies and encouraging early‐phase clinical activity in combination wit...

Full description

Bibliographic Details
Main Authors: Paul G. Richardson, Arnon Nagler, Dina Ben‐Yehuda, Ashraf Badros, Parameswaran N. Hari, Roman Hajek, Ivan Spicka, Hakan Kaya, Richard LeBlanc, Sung‐Soo Yoon, Kihyun Kim, Joaquin Martinez‐Lopez, Moshe Mittelman, Ofer Shpilberg, Paul Blake, Teru Hideshima, Kathleen Colson, Jacob P. Laubach, Irene M. Ghobrial, Merav Leiba, Moshe E. Gatt, Peter Sportelli, Michael Chen, Kenneth C. Anderson
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:eJHaem
Subjects:
Akt inhibition
bortezomib
multiple myeloma
perifosine
proteasome inhibition
Online Access:https://doi.org/10.1002/jha2.4

Internet

https://doi.org/10.1002/jha2.4

Similar Items